Human antibodies that bind human TNFα
Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d =10 −8 M or less), a slow off rate for hTNFα dissociation (e.g., K off =10 −3 sec −1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
1. An isolated human antibody, or an antigen-binding portion thereof, that dissociates from human TNFα (hTNFα) with a K d of 1×10 −8 M or less and a K off rate constant of 1×10 −3 s −1 or less, both determined by surface plasmon resonance, and inhibits human TNFα-induced expression of ELAM-1 on human umbilical vein endothelial cells.
2. The isolated human antibody, or antigen-binding portion thereof, of claim 1 , which dissociates from human TNFα with a K off rate constant of 5×10 −4 s −1 or less.
3. The isolated human antibody, or antigen-binding portion thereof, of claim 1 , which dissociates from human TNFα with a K off rate constant of 1×10 −4 s −1 or less.
4. The isolated human antibody, or antigen-binding portion thereof, of claim 1 , which is a recombinant antibody, or antigen-binding portion thereof.
5. The isolated human antibody of claim 1 , which has an IgG1 heavy chain constant region.
6. The isolated human antibody of claim 1 , which has an IgG4 heavy chain constant region.
7. A pharmaceutical composition comprising the isolated human antibody of claim 1 , and a pharmaceutically acceptable carrier.